Allogene Therapeutics Inc (ALLO) Stock: What Does the Chart Say Tuesday?

The market has been down on Allogene Therapeutics Inc (ALLO) stock recently. ALLO gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Allogene Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ALLO!

See Full ALLO Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ALLO Stock Today?

Allogene Therapeutics Inc (ALLO) stock is trading at $4.39 as of 12:19 PM on Tuesday, Mar 19, a rise of $0.19, or 4.53% from the previous closing price of $4.20. The stock has traded between $4.12 and $4.39 so far today. Volume today is light. So far 719,685 shares have traded compared to average volume of 2,781,542 shares. To screen for more stocks like Allogene Therapeutics Inc click here.

More About Allogene Therapeutics Inc

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Click Here to get the full Stock Report for Allogene Therapeutics Inc stock.